FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1924186013> ?p ?o ?g. }

• W1924186013 endingPage "802" @default.
• W1924186013 startingPage "793" @default.
• W1924186013 abstract "Sera of patients with chronic Chagas' disease (American trypanosomiasis) contain elevated levels of anti-alpha-galactosyl antibodies that are lytic to Trypanosoma cruzi. The T. cruzi trypomastigote F2/3 antigen complex recognized by these antibodies runs as a broad smear on SDS/PAGE [Almeida, Krautz, Krettli and Travassos (1993) J. Clin. Lab. Anal. 7, 307-316]. Treatment of T. cruzi trypomastigote cells with bacterial phosphatidylinositol-specific phospholipase C (PI-PLC) abolished most of their reactivity to chronic Chagas'-disease ((Chagasic, Ch) anti-alpha-galactosyl antibodies (anti-Gal). The F2/3 antigen complex, purified by solvent extraction and hydrophobic-interaction chromatography, contained 60% carbohydrate by weight and substantial amounts of Thr, Ser, Glx, Asx, Gly, Ala and Pro, but relatively few hydrophobic amino acids. The presence of myoinositol, ethanolamine and 1-O-hexadecylglycerol suggested the presence of glycosyl-phosphatidylinositol membrane anchors. This was confirmed by PI-PLC treatment, which rendered the F2/3 molecules hydrophilic and reactive to anti-(cross-reacting determinant) antibodies. The majority of the GlcNAc content of the F2/3 antigens was found at the reducing termini of oligosaccharides in O-glycosidic linkage to Thr residues. These O-linked oligosaccharides could be released by beta-elimination and by mild hydrazinolysis. The smallest released oligosaccharitol that was reactive with the Ch anti-Gal was Gal alpha 1-3Gal beta 1-4GlcNAcol (where GlcNAcol is N-acetyl-glucosaminitol). Several other Gal-containing oligosaccharitols were observed, most of which were branched and contained 4,6-di-O-substituted GlcNAcol at their reducing termini. About half of the total released oligosaccharitols could bind to immobilized Ch anti-Gal, but none of them bound to the anti-Gal isolated from normal human sera. These data suggest that the specificities of the Ch anti-Gal are quite different from the natural anti-Gal isolated from normal human sera. Therefore, these novel T. cruzi O-linked oligosaccharides are highly immunogenic under the conditions of natural infection and are the targets for lytic Ch anti-Gal." @default.
• W1924186013 created "2016-06-24" @default.
• W1924186013 creator A5045896098 @default.
• W1924186013 creator A5054601444 @default.
• W1924186013 creator A5069607510 @default.
• W1924186013 creator A5074953319 @default.
• W1924186013 date "1994-12-15" @default.
• W1924186013 modified "2023-10-03" @default.
• W1924186013 title "Lytic anti-<i>α</i>-galactosyl antibodies from patients with chronic Chagas' disease recognize novel <i>O</i>-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of <i>Trypanosoma cruzi</i>" @default.
• W1924186013 cites W1440686653 @default.
• W1924186013 cites W1481480776 @default.
• W1924186013 cites W148465568 @default.
• W1924186013 cites W1485814238 @default.
• W1924186013 cites W1492411340 @default.
• W1924186013 cites W1521762031 @default.
• W1924186013 cites W1532438728 @default.
• W1924186013 cites W1561974851 @default.
• W1924186013 cites W1570068227 @default.
• W1924186013 cites W1590549770 @default.
• W1924186013 cites W1601059079 @default.
• W1924186013 cites W1609959936 @default.
• W1924186013 cites W1618744733 @default.
• W1924186013 cites W1943730733 @default.
• W1924186013 cites W1949449831 @default.
• W1924186013 cites W1971942838 @default.
• W1924186013 cites W1990923023 @default.
• W1924186013 cites W2002534697 @default.
• W1924186013 cites W2002738745 @default.
• W1924186013 cites W2005442970 @default.
• W1924186013 cites W2007863471 @default.
• W1924186013 cites W2008689132 @default.
• W1924186013 cites W2011640394 @default.
• W1924186013 cites W2021549033 @default.
• W1924186013 cites W2027097213 @default.
• W1924186013 cites W2039939971 @default.
• W1924186013 cites W2044324768 @default.
• W1924186013 cites W2059665344 @default.
• W1924186013 cites W2075109332 @default.
• W1924186013 cites W2087142903 @default.
• W1924186013 cites W2096294692 @default.
• W1924186013 cites W2414632560 @default.
• W1924186013 cites W2424468219 @default.
• W1924186013 cites W970712027 @default.
• W1924186013 doi "https://doi.org/10.1042/bj3040793" @default.
• W1924186013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1137404" @default.
• W1924186013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7818483" @default.
• W1924186013 hasPublicationYear "1994" @default.
• W1924186013 type Work @default.
• W1924186013 sameAs 1924186013 @default.
• W1924186013 citedByCount "214" @default.
• W1924186013 countsByYear W19241860132012 @default.
• W1924186013 countsByYear W19241860132013 @default.
• W1924186013 countsByYear W19241860132014 @default.
• W1924186013 countsByYear W19241860132015 @default.
• W1924186013 countsByYear W19241860132016 @default.
• W1924186013 countsByYear W19241860132017 @default.
• W1924186013 countsByYear W19241860132018 @default.
• W1924186013 countsByYear W19241860132019 @default.
• W1924186013 countsByYear W19241860132020 @default.
• W1924186013 countsByYear W19241860132021 @default.
• W1924186013 countsByYear W19241860132022 @default.
• W1924186013 countsByYear W19241860132023 @default.
• W1924186013 crossrefType "journal-article" @default.
• W1924186013 hasAuthorship W1924186013A5045896098 @default.
• W1924186013 hasAuthorship W1924186013A5054601444 @default.
• W1924186013 hasAuthorship W1924186013A5069607510 @default.
• W1924186013 hasAuthorship W1924186013A5074953319 @default.
• W1924186013 hasBestOaLocation W19241860132 @default.
• W1924186013 hasConcept C108625454 @default.
• W1924186013 hasConcept C112418997 @default.
• W1924186013 hasConcept C136764020 @default.
• W1924186013 hasConcept C147483822 @default.
• W1924186013 hasConcept C153911025 @default.
• W1924186013 hasConcept C159047783 @default.
• W1924186013 hasConcept C159654299 @default.
• W1924186013 hasConcept C179264091 @default.
• W1924186013 hasConcept C184235292 @default.
• W1924186013 hasConcept C185592680 @default.
• W1924186013 hasConcept C203014093 @default.
• W1924186013 hasConcept C2777625466 @default.
• W1924186013 hasConcept C2780610907 @default.
• W1924186013 hasConcept C41008148 @default.
• W1924186013 hasConcept C55493867 @default.
• W1924186013 hasConcept C71928629 @default.
• W1924186013 hasConcept C86803240 @default.
• W1924186013 hasConcept C89423630 @default.
• W1924186013 hasConceptScore W1924186013C108625454 @default.
• W1924186013 hasConceptScore W1924186013C112418997 @default.
• W1924186013 hasConceptScore W1924186013C136764020 @default.
• W1924186013 hasConceptScore W1924186013C147483822 @default.
• W1924186013 hasConceptScore W1924186013C153911025 @default.
• W1924186013 hasConceptScore W1924186013C159047783 @default.
• W1924186013 hasConceptScore W1924186013C159654299 @default.
• W1924186013 hasConceptScore W1924186013C179264091 @default.
• W1924186013 hasConceptScore W1924186013C184235292 @default.
• W1924186013 hasConceptScore W1924186013C185592680 @default.
• W1924186013 hasConceptScore W1924186013C203014093 @default.
• W1924186013 hasConceptScore W1924186013C2777625466 @default.

• next